2023-04-26 11:14:23
Public comment launched with today’s release of the EU Pharma Regulatory Framework.
We will analyze the documents following their publication today and, in any case, also comment on them. However, the draft legislation that was made public a few weeks ago has already shown that the focus is probably more on restrictions and limitations than on incentives and subsidies. If this continues in the current version, EU policy will do the whole of Europe a disservice and will in no way contribute to a future-proof and crisis-proof EU drug system
Mag. Alexander Herzog, Secretary General of PHARMIG
Vienna (OTS) – The EU Commission will shortly publish the long-awaited proposal for a revision of the EU legal framework “Pharma Legislation”. This will then be able to be commented on by EU citizens, institutions and companies. With regard to a final version, it is of the utmost importance for the pharmaceutical industry that drug research and access are not jeopardized by restrictions and unworkable specifications and that Europe is not made even more dependent on other regions as a result.
“We will analyze the documents following their publication today and, in any case, also comment on them. However, the draft legislation that was made public a few weeks ago has already shown that the focus is probably more on restrictions and limitations than on incentives and subsidies. If this continues in the current version, EU policy will do the whole of Europe a disservice and will in no way contribute to a future-proof and crisis-proof EU drug system.”
warns Alexander Herzog, Secretary General of PHARMIG.
Although the goals of the drug strategy are 100 percent supported by the pharmaceutical industry, the way there must not be marked by hurdles and difficulties. “Otherwise we will not achieve any more drug research, faster and more comprehensive access to drugs and no intensification of antibiotics research,” says Herzog.
About PHARMIG: PHARMIG is the voluntary interest group of the Austrian pharmaceutical industry. The association currently has around 120 members (as of April 2023), who cover a good 95 percent of the drug market. PHARMIG and its member companies stand for the best possible security of supply with medicines in the healthcare sector and ensure social and medical progress through quality and innovation.
Questions & contact:
PHARMIG – Association of the Austrian Pharmaceutical Industry
Peter Richter, BA MA MBA
Head of Communications & PR
+43 664 8860 5264
peter.richter@pharmig.at
www.pharmig.at
1682507791
#Pharma #legislation #prove #disservice #Europe
